共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
3.
Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators
下载免费PDF全文
![点击此处可从《Pharmacoepidemiology and drug safety》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jonathan Bates Craig S. Parzynski Sanket S. Dhruva Andreas Coppi Richard Kuntz Shu‐Xia Li Danica Marinac‐Dabic Frederick A. Masoudi Richard E. Shaw Frederick Warner Harlan M. Krumholz Joseph S. Ross 《Pharmacoepidemiology and drug safety》2018,27(8):848-856
4.
5.
6.
Growth in health information systems presents opportunities to enhance postmarketing safety surveillance of medical products. Spontaneous suspected side effect reports provide the foundation, but we need to 'proactively' improve their quality and our strategies to seek signals. In our more familiar 'reactive' mode, we examine hypotheses from inquiries or publicity. Such responsive evaluations remain essential but may miss latent information on unsuspected risks. Efficient techniques to disclose hidden clusters and associations may emerge through adaptation of approaches from industrial quality control and other disciplines. Data-driven techniques like exploratory analysis, control charts, and time series modeling may help in sifting through accumulated data and in screening consecutive submissions to discern hints of new product hazards or of more specific understanding about previously identified potential side effects. We also need to cultivate non-spontaneous data for hypothesis generation as well as testing, the systematic epidemiologic evaluation of questions and concerns. This hypothesis testing function will assume greater importance if proactive safety surveillance methods yield larger numbers of putatively positive findings. Whether from spontaneous reports or other sources, signals that could have arisen by chance alone usually represent only clues to potential hazards until or unless they can be verified through independent studies. 相似文献
7.
8.
目的 针对生物源性医疗器械的病毒安全性进行分析、研究.方法 文献检索并分析生物源性医疗器械的病毒安全性.结果 总结出生物源性医疗器械病毒安全性的控制、效果验证及检测方法.结论 我国生物源性医疗器械存在病毒安全性控制问题,其质量标准有待完善. 相似文献
9.
In the light of escalating use of medical devices, stringent regulatory standards are required to ensure that the devices are safe, well studied and have least adverse reactions. Recently introduced guidelines and the amendment in the law will provide adequate guidance for both the manufacturers and competent authorities to manage cases efficiently and appropriately. India has emerged as one of the leaders in pharmaceutical industry. Like many other amendments in Drugs and Cosmetics Act that have boosted the global confidence in pharmaceutical industry in India, guidelines for devices will encourage the much needed research in medical devices. Pharmacy personnel can certainly play an important role in the regulation of medical devices. Safety, risks, effectiveness and performance of the medial devices need to be well established and regulated properly. It is hoped that the guidelines are implemented and regulated properly with effective outcome. 相似文献
10.
11.
Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non‐compliance: Survey among French‐speaking health care professionals and patients in Belgium
下载免费PDF全文
![点击此处可从《Pharmacoepidemiology and drug safety》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Mélanie Lelubre Jamila Hamdani Christelle Senterre Karim Amighi Marion Peres Marie‐Paule Schneider Olivier Bugnon Carine De Vriese 《Pharmacoepidemiology and drug safety》2018,27(6):668-673
12.
13.
14.
近年来,欧盟和美国对于监测上市后药品的安全性愈加重视,在加强各自的药品上市后安全性监测体系方面采取了不少新举措。本文分析了欧美药品上市后安全性监测体系的发展趋势,并探讨了对于我国的借鉴意义。 相似文献
15.
16.
17.
国家对医疗器械实行分类管理,第一类医疗器械无需临床试验,第二类、第三类医疗器械生产注册之前应当通过临床试验(临床试用或临床验证)。医疗器械临床试验的伦理审查要点主要包括试验的科学设计;试验的风险和受益评估,区分重大风险临床试验和非重大风险临床试验;知情同意;受试人群的选择;受试者的医疗和保护等。医疗器械临床试验的批准标准和医疗器械紧急使用都应该符合相应的标准。 相似文献
18.
19.
目的 结合安徽省医疗器械不良事件监测工作,为开展医疗器械不良事件监测提供技术参考。方法 利用国家药品不良反应监测中心数据库软件,对2005年全省39例医疗器械不良事件报告进行统计分析,对目前存在的问题和应对措施进行了初步探讨。结果 骨科植入物、宫内节育器等不良事件发生率较高。结论 应强化医疗器械不良事件报告制度,为保障公众用械安全服务。 相似文献